Compare DDD & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | OABI |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.8M | 239.0M |
| IPO Year | N/A | N/A |
| Metric | DDD | OABI |
|---|---|---|
| Price | $1.93 | $2.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.75 | ★ $6.67 |
| AVG Volume (30 Days) | ★ 2.9M | 571.9K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $391,651,000.00 | $21,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.31 | $66.19 |
| P/E Ratio | $18.14 | ★ N/A |
| Revenue Growth | N/A | ★ 3.36 |
| 52 Week Low | $1.32 | $1.22 |
| 52 Week High | $5.00 | $4.08 |
| Indicator | DDD | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 73.35 |
| Support Level | $1.70 | $1.90 |
| Resistance Level | $2.29 | $2.04 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 38.14 | 88.68 |
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.